Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Aromatase inhibitor therapy is in France the adjuvant reference treatment for postmenopausal
women with early-stage breast cancer. This treatment induces bone loss and a higher risk of
fractures.
This study aimed to document the effect of bisphosphonate therapy in preventing bone loss and
osteoporotic fractures in postmenopausal women with aromatase inhibitor treatment for breast
cancer